For patients with potentially resectable HER2-positive GC, the malignant biological behaviours of the tumour worsen surgical outcomes and prognoses; thus, exploring the optimal preoperative treatment options for patients with potentially resectable HER2-positive GC is important. The gene discussed is ERBB2; the disease is gastric cancer.